Stay updated with breaking news from Darin Messina. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
–All primary and secondary endpoints were met for both Phase 3 studies .–Results support BoNT/E as a novel botulinum neurotoxin serotype E characterized by a rapid onset of action as early as 8...
/PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced positive topline results from the second of three Phase 3 clinical studies...
Allergan Aesthetics, an AbbVie company (ABBV), reported positive topline results from the second of three Phase 3 clinical studies evaluating onabotulinumtoxinA for the treatment of moderate to severe platysma prominence associated with platysma muscle activity.
–Data results shared across facial injectables, body contouring and skincare portfolio highlights Allergan Aesthetics' continued commitment to advancing...